Benzinga | Oct 12, 2021 06:19AM EDT

Raymond James Downgrades Flexion Therapeutics to Market Perform

Raymond James analyst Elliot Wilbur downgrades Flexion Therapeutics (NASDAQ:FLXN) from Strong Buy to Market Perform.